Boehringer Ingelheim secures FDA approval for Hernexeos, a lung cancer treatment, under the Commissioner’s Priority Program. This marks the second drug to receive approval through this expedited pathway, following USAntibiotics’ Augmentin XR.
Hernexeos is the second drug to secure an FDA approval under the agency’s priority voucher scheme, following in the footsteps of USAntibiotics’ Augmentin XR, which was granted the ticket in December 2025.
Original title: “Boehringer Wins Speedy Lung Cancer Approval Under Commissioner’s Priority Program”